JP2018536637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536637A5 JP2018536637A5 JP2018519321A JP2018519321A JP2018536637A5 JP 2018536637 A5 JP2018536637 A5 JP 2018536637A5 JP 2018519321 A JP2018519321 A JP 2018519321A JP 2018519321 A JP2018519321 A JP 2018519321A JP 2018536637 A5 JP2018536637 A5 JP 2018536637A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- substituted
- ester
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3308DE2015 | 2015-10-14 | ||
| IN3308/DEL/2015 | 2015-10-14 | ||
| PCT/US2016/056714 WO2017066366A1 (en) | 2015-10-14 | 2016-10-13 | Selective nr2b antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536637A JP2018536637A (ja) | 2018-12-13 |
| JP2018536637A5 true JP2018536637A5 (cg-RX-API-DMAC7.html) | 2019-11-21 |
| JP6938485B2 JP6938485B2 (ja) | 2021-09-22 |
Family
ID=57223768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519321A Active JP6938485B2 (ja) | 2015-10-14 | 2016-10-13 | 選択的ｎｒ２ｂアンタゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10344020B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3362441B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6938485B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180063306A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108137543B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016340237A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018006537A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3001890A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201890946A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2818254T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258603A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018004256A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017066366A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303357A (en) * | 2020-12-04 | 2023-08-01 | Novartis Ag | Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression |
| US11646085B2 (en) | 2021-06-17 | 2023-05-09 | Sandisk Technologies Llc | Toggle mode frequency optimization by dynamic ODT matching for non-volatile memory |
| CN116354923B (zh) * | 2021-12-27 | 2025-05-09 | 江苏恩华药业股份有限公司 | 一种含氮杂环化合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022728B2 (en) * | 2001-03-09 | 2006-04-04 | Abbott Laboratories | Benzimidazoles that are useful in treating male sexual dysfunction |
| US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
| MXPA05013151A (es) | 2003-06-04 | 2006-03-17 | Merck & Co Inc | 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b. |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| BRPI0813001A2 (pt) | 2007-06-29 | 2019-09-24 | Univ Emory | composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica |
| JP2009067784A (ja) * | 2007-08-21 | 2009-04-02 | Shionogi & Co Ltd | 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤 |
| EP2163541A1 (en) | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
| BR112012020142A2 (pt) | 2010-02-11 | 2020-08-18 | Northwestern University | moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos. |
| EP3087067B1 (en) * | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| JP6843853B2 (ja) * | 2015-10-14 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 選択的ｎｒ２ｂアンタゴニスト |
-
2016
- 2016-10-13 ES ES16790475T patent/ES2818254T3/es active Active
- 2016-10-13 CN CN201680060583.4A patent/CN108137543B/zh active Active
- 2016-10-13 EP EP16790475.4A patent/EP3362441B1/en active Active
- 2016-10-13 AU AU2016340237A patent/AU2016340237A1/en not_active Abandoned
- 2016-10-13 US US15/767,386 patent/US10344020B2/en active Active
- 2016-10-13 JP JP2018519321A patent/JP6938485B2/ja active Active
- 2016-10-13 KR KR1020187013126A patent/KR20180063306A/ko not_active Abandoned
- 2016-10-13 MX MX2018004256A patent/MX2018004256A/es unknown
- 2016-10-13 BR BR112018006537A patent/BR112018006537A2/pt not_active Application Discontinuation
- 2016-10-13 WO PCT/US2016/056714 patent/WO2017066366A1/en not_active Ceased
- 2016-10-13 EA EA201890946A patent/EA201890946A1/ru unknown
- 2016-10-13 CA CA3001890A patent/CA3001890A1/en not_active Abandoned
-
2018
- 2018-04-10 IL IL258603A patent/IL258603A/en unknown
-
2019
- 2019-07-03 US US16/502,684 patent/US10961229B2/en active Active